Opinion|Videos|June 24, 2024
Recent Data from COMMIT in dMMR/MSI-High Metastatic Colorectal Cancer
Mark A. Lewis, MD, discusses recent data from the COMMIT trial investigating first-line treatment of patients with deficient DNA mismatch repair or microsatellite instability–high metastatic colorectal cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
The phase 2 PEGASUS trial of ctDNA-guided adjuvant therapy in high-risk stage II/III colon cancer missed its primary end point but reduced neurotoxicity.
This marks the fourth submission to the FDA for approval of rivoceranib plus camrelizumab for this first-line indication in hepatocellular carcinoma.
The FDA granted FTD to opantistomig, a PD-L1/4-1BB bispecific antibody, for first-line treatment of biliary tract cancer.
RYZ101, a targeted alpha radiopharmaceutical, boosts progression-free survival in SSTR+ GEP-NETs after progression, offering a promising post-¹⁷⁷Lu option.
The approval of the adjuvant atezolizumab combination in dMMR colon cancer is supported by the phase 3 ATOMIC trial.
FDA grants 2 breakthrough therapy designations to Temab-A, speeding development for hard-to-treat colorectal cancer and c-Met–expressing lung cancer.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Amivantamab vs. Emerging EGFR Bispecifics in HNSCC
2
Durability of PFS and OS Benefit vs. Historical Control
3
How Disease Burden Shapes First-Line RCC Treatment Selection
4
Rivoceranib Plus Camrelizumab Resubmitted to FDA in Frontline HCC
5